-
Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
July 21, 2023 -
Conclusion of two agreements in the area of data management and biostatistics for RVU120 Phase II clinical trials in hematology
Read More
July 14, 2023 -
Conclusion of two agreements with Zakłady Farmaceutyczne Polpharma S.A. in the area of RVU120 active substance (API) production for Phase II clinical trials
Read More
July 6, 2023 -
Registration of an amendment to the Articles of Association of the Company concerning conditional increase in the share capital of the Company
Read More
June 19, 2023 -
Appointment of new Members of the Supervisory Board of Ryvu Therapeutics S.A.
Read More
June 14, 2023 -
Shareholders controlling at least 5% of the votes at the General Shareholders Meeting of Ryvu Therapeutics S.A. convened on June 14th, 2023
Read More
June 14, 2023 -
Resolutions adopted by the General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
June 14, 2023 -
Recommendation of Ryvu’s project for funding by the Medical Research Agency
Read More
June 13, 2023 -
Publication of the updated clinical and preclinical data on RVU120
Read More
June 9, 2023 -
Correction of the current report on the convening of the Company’s Annual General Meeting
Read More
May 26, 2023 -
Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
Read More
May 25, 2023 -
Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
Read More
May 25, 2023 -
Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program
Read More
May 25, 2023 -
Notification from person discharging managerial responsibilities in the Company due to execution of the Stock Grant Program – Article 19 of MAR
Read More
May 25, 2023 -
Notification from a person discharging managerial responsibilities in the Company – Article 19 of MAR
Read More
May 23, 2023 -
Convening the Ordinary General Shareholders Meeting of Ryvu Therapeutics S.A.
Read More
May 18, 2023 -
Notification from PTE Allianz Polska S.A. of a change in its share in the total number of votes in the Company
Read More
May 16, 2023 -
New clinical and preclinical data on RVU120 to be presented at the upcoming 2023 European Hematology Association Congress
Read More
May 11, 2023 -
Conclusion of an agreement for the issuance of subscription warrants to the European Investment Bank
Read More
May 5, 2023 -
Conclusion of the agreements concerning Phase II start-up services for RVU120 clinical studies in AML/HR-MDS
Read More
April 20, 2023
Report: Current Stock Reports
Title